The opposing relationships between CDK2/CDK3 (negative) and CDK5 (positive) with regulatory T cell populations suggest that selective CDK inhibition could serve dual therapeutic functions—blocking tumour proliferation while simultaneously enhancing anti‐tumour immunity. Here, CDK3 is linked to neoplasm.